Artelo Biosciences, Inc. (ARTL) Fair Value 2026

ARTL · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.0 /10

32 fundamental signals · 7 models active

Value Trap Risk

LOW (27/100)

Quick Summary — As of 2026-07-15, Artelo Biosciences, Inc. (ARTL) trades at $1.15, approximately 40% below CirclFi’s Bayesian DCF fair value of $1.92. QOC: 4.0/10. Value Trap Risk: 27/100 (LOW). 7/13 models active.

Key Facts

Ticker
ARTL
Price
$1.15
Quality Score
4.0/10
Value Trap Risk
27/100
Models Active
7/13
Last Updated
Strength: First Chicago suggests +420.2% upside with 14% confidence
Risk: Below-average Quality Score of 4.0/10 signals weak fundamentals

Is Artelo Biosciences, Inc. (ARTL) Undervalued or Overvalued in 2026?

According to CirclFi’s 7-model valuation engine, Artelo Biosciences, Inc. (ARTL) appears undervalued as of : the median of 7 independent fair value estimates is $2.47, 115.1% above the current price of $1.15. Estimates range from $0.27 to $5.98. ARTL scores 4.0/10 on fundamental quality and 27/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Artelo Biosciences, Inc. Stock in 2026? →

Valuation Matrix

7 Intrinsic Value Models vs. Current Price ($1.15)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $1.92 +66.6%
CUCE Ensemble
Low Conviction
 $2.47 +115.1%
First Chicago
Low Conviction
 $5.98 +420.2%

Unlock the Full Matrix

Access 4 additional models including ML-RIV, Dynamic NAV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 7 Models →

Cancel anytime · No contracts · Instant access

What Is Artelo Biosciences, Inc. (ARTL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Artelo Biosciences, Inc.'s intrinsic value is estimated at a composite fair value of $2.70. While the stock appears modestly undervalued at $1.15 (implied upside of +134.6%), our analysis suggests a thinner margin of safety across 5 of 7 bullish models. Notably, First Chicago sees the most upside at +420.2% (fair value: $5.98), while ML-RIV is the most conservative at -76.7% ($0.27). The spread between these extremes — +496.9% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About ARTL?

7 of 13 models are currently active for ARTL. Of these, 5 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates ARTL's intrinsic value at $1.92, implying +66.6% upside from the current price. See which stocks rank higher →

How Does ARTL Rank in Biotechnology?

Among 76 Biotechnology stocks, ARTL ranks #66 by Quality of Company score. CirclFi's QOC score of 4.0/10 evaluates 32 fundamental signals. A score of 4.0 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Artelo Biosciences, Inc. competes in an environment where cash runway (months) often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is ARTL a Value Trap?

CirclFi's Value Trap algorithm assigns ARTL a score of 27/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

7 of 13 models are active for Artelo Biosciences, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Artelo Biosciences, Inc. is rated at 4.0/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

The gap between the most bullish and bearish model spans +496.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ARTL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ARTL's 7 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Artelo Biosciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

8 related Biotechnology stocks with 13-model coverage

ADMAADMA Biologics IncQOC 10.0AUPHAurinia Pharmaceuticals IncQOC 9.5ACADACADIA Pharmaceuticals Inc.QOC 9.4ALNYAlnylam Pharmaceuticals, Inc.QOC 8.3ACRSAclaris Therapeutics, Inc.QOC 7.4ABCLAbCellera Biologics Inc.QOC 7.1ARCTArcturus Therapeutics Holdings QOC 7.0ARVNArvinas, Inc.QOC 6.9

Read investment analysis: ADMA · AUPH · ACAD · ALNY · ACRS

See all Biotechnology stocks ranked →

Frequently Asked Questions About Artelo Biosciences, Inc.

What is Artelo Biosciences, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Artelo Biosciences, Inc. (ARTL) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $1.92. The Quality of Company score is 4.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ARTL overvalued or undervalued right now?

At $1.15, 5 of 7 active models suggest ARTL may be undervalued, while 2 indicate potential overvaluation. The median of all 7 fair value estimates is $2.47, 115.1% above the current price of $1.15 — a consensus view that ARTL is undervalued. The assessment depends on which methodology best fits Artelo Biosciences, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.0 mean for ARTL?

Artelo Biosciences, Inc.'s QOC of 4.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ARTL?

CirclFi analyzes ARTL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 7 of 13 are active for this stock. Read the full methodology →

Is ARTL a value trap in 2026?

Artelo Biosciences, Inc.'s Value Trap score is 27/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 7-model valuation engine, Artelo Biosciences, Inc. (ARTL) has a median fair value of $2.47 — 115.1% above the current price of $1.15 — as of 2026-07-15.” Source: circlfi.com/stock/ARTL/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 7 mathematical frameworks give you clarity on ARTL.

Unlock All 7 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access